FIGURE 6.

Metabolic pathways with statistically different abundance in skin microbiomes of subjects with rosacea before treatment (baseline) and after treatment with E-BPO (Week 8/Visit 6) (Intent-to-Treat Population). LDA effect size (LEfse) rank plot of differentially abundant pathways in untreated (baseline) versus E-BPO cream, 5%, treated samples (Week 8). Computed LDA scores (log10) of the relative abundance difference between untreated and treated groups are presented. Negative LDA scores (brown) are enriched in the untreated (baseline) group, while positive LDA scores (purple) are enriched in the E-BPO cream, 5%, group, and the length is the LDA effect size. LDA score ≥2.0 or ≤–2.0 with a P-value ≤0.05 was considered significantly enriched using Kruskal-Wallis (to detect features with significant differential abundance) and Wilcoxon tests (for pairwise comparisons). E-BPO: microencapsulated benzoyl peroxide cream; LDA: linear discriminant analysis; NAD: nicotinamide adenine dinucleotide